AI: game-changing or just another buzzword? Roger Palframan from UCB sees artificial intelligence as one type of enabling advanced analytics tool that helps people make better – and faster – decisions. Here, Roger explains how AI can benefit research scientists, clinical scientists, and others. He also talks us through UCB’s drug-discovery collaboration with Microsoft through their “AI for Health” program.
 

James Strachan, Deputy Editor
 
FORMULATION
3D Printing: Democratizing Precision Medicine
06/09/2021 | Dayanjan Wijesinghe, Tom Knapman
If the industry can figure out 3D printing’s regulatory hurdles, we may be on the cusp of a revolution: the democratization of personalized precision.
DIGITAL TECHNOLOGIES
Beyond Drug Development
06/08/2021
AI opens up new opportunities in R&D – and also provides pharma companies with new ways to connect with patients for better outcomes.
BUSINESS PRACTICE
Celebration of Design
06/04/2021 | Maryam Mahdi
Implementing sustainable practices for a better future.
COVID-19
Navigating the Uncertainty
06/10/2021 | Lori Muffly
Lori Muffly believes collaboration and innovation – bolstered during the COVID-19 pandemic – will guide the future of stem cell transplant.
 
White Papers
Measurement of the concentration of Adeno-Associated Virus

For virus development and production, it is important to know the virus concentration at different stages of the process, to optimize the clone used as well as the production yields. Read more
Characterization of the Size and Concentration of Liposomes

Liposomes are nowadays frequently used as drug delivery systems, and as such requires that they are well characterized for manufacturing and batch release. Read more
 
Product Profile
Stemline® XF MSC Medium

Stemline® XF MSC Medium supports consistent expansion performance of MSCs in planar and microcarrier culture formats. Learn more about how to bring higher yield and functionality to your process.
 
Special Promotions
Achieve confidence in your proprietary media supply

Accelerate your biologics’ journey from process to patient by collaborating with a global media manufacturer with harmonized manufacturing sites and the capacity to offer unrivaled supply assurance. Find out more
How to Accelerate Lot-Release and In-Process Mycoplasma Testing

PCR-based mycoplasma testing for lot-release of biotherapeutics has grown in acceptability by regulatory agencies worldwide. Learn about regulatory guidance and considerations for manufacturers who want to shift to a rapid assay. Find out more
We Need to Talk About Cell and Gene Therapy

Experts explain why the advanced therapy field must progress with the needs of the patient – as defined by the patient – in mind in The Medicine Maker Cell and Gene Therapy Supplement.
A dedicated cell + gene therapy newsletter from The Medicine Maker team

Join 1,000s of peers from across the pharmaceutical, investment, and regulatory sectors for expert insight, analysis and words of wisdom on everything cell + gene therapy. Subscribe Now
 
Must-See Events Worldwide

We work with event organizers from all around the world to help bring the pharma industry together, from large congresses to intimate meetings that fit around a table. Discover some of the events that we partner with and and stay up-to-date with the latest developments.
Find out more
This email was sent to {~email~} by info@themedicinemaker.com. To ensure delivery of emails to your inbox, please add info@themedicinemaker.com to your address book or safe sender list. To view online, please click here.

Create or manage your account here
Unsubscribe here

The Medicine Maker is a brand of Texere Publishing Limited

Texere Publishing Limited, Booths Park 1,
Chelford Road, Knutsford, WA16 8GS, UK
Registered Company Number: 08113419
Texere Publishing Inc., 115 Broadway, FL 5,
New York, NY 10006, USA
Federal Identification Number: 81-4613586